Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.
What happened
FDA reviewed records the company submitted after FDA's April 3, 2023 request for records under section 704(a)(4) of the Food, Drug, and Cosmetic Act; no inspection dates are stated. FDA found the company did not test incoming drug ingredients for identity, relied on supplier test reports without qualifying suppliers or verifying the reports, and did not test isopropyl alcohol for methanol. FDA also found no long-term stability data or stability program documents to support product expiry dates.
What FDA found
The firm did not test each incoming ingredient lot for identity and conformity with purity, strength, and quality specifications.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm released a drug ingredient based on the supplier's test report and did not qualify the supplier or verify the report.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not test incoming isopropyl alcohol for methanol; its supplier test report had no methanol specification or result.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not provide identity testing results for other raw materials used in drug products shipped from the facility.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm provided accelerated stability reports for three products but no long-term stability studies or stability program documents to support expiry dates.
What FDA wants
FDA asks the firm to correct violations promptly and respond in writing within 15 working days with a material-system review, component test specifications and test-report verification plan, methanol test results for U.S.-shipped hand sanitizer batches within expiry, and other corrective actions. FDA also strongly recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drugs or hand sanitizer from this manufacturer
- U.S. importers and distributors of hand sanitizer
- companies relying on supplier test reports for drug ingredients
This is a summary. Read the original letter on fda.gov.